Free Trial

Kezar Life Sciences (KZR) Stock Price, News & Analysis

+0.03 (+4.55%)
(As of 08:50 AM ET)
Today's Range
50-Day Range
52-Week Range
3,526 shs
Average Volume
706,248 shs
Market Capitalization
$51.69 million
P/E Ratio
Dividend Yield
Price Target

Kezar Life Sciences MarketRank™ Stock Analysis

Analyst Rating
2.33 Rating Score
1,519.8% Upside
$11.00 Price Target
Short Interest
3.91% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
1.44mentions of Kezar Life Sciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($1.24) to ($1.27) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.49 out of 5 stars

Medical Sector

111th out of 915 stocks

Pharmaceutical Preparations Industry

39th out of 435 stocks

KZR stock logo

About Kezar Life Sciences Stock (NASDAQ:KZR)

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

KZR Stock Price History

KZR Stock News Headlines

Could You Retire on a Single AI Stock (trading for only $15)?
This is the perfect AI stock...And it's currently trading for only $15. With just one investment in this company, you could potentially set yourself up for massive financial gains.
Kezar Life Sciences Inc (KZR)
Could You Retire on a Single AI Stock (trading for only $15)?
This is the perfect AI stock...And it's currently trading for only $15. With just one investment in this company, you could potentially set yourself up for massive financial gains.
Kezar Life Sciences, Inc. (KZR)
See More Headlines
Receive KZR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$7 million
Book Value
$2.58 per share


Free Float
Market Cap
$49.44 million
Not Optionable
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

KZR Stock Analysis - Frequently Asked Questions

How have KZR shares performed this year?

Kezar Life Sciences' stock was trading at $0.9474 at the start of the year. Since then, KZR shares have decreased by 28.3% and is now trading at $0.6791.
View the best growth stocks for 2024 here

How were Kezar Life Sciences' earnings last quarter?

Kezar Life Sciences, Inc. (NASDAQ:KZR) released its quarterly earnings data on Thursday, May, 9th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.04.

When did Kezar Life Sciences IPO?

Kezar Life Sciences (KZR) raised $70 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair served as the underwriters for the IPO.

How do I buy shares of Kezar Life Sciences?

Shares of KZR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Kezar Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kezar Life Sciences investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Pfizer (PFE), VYNE Therapeutics (vyne), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

This page (NASDAQ:KZR) was last updated on 7/18/2024 by Staff

From Our Partners